<DOC>
	<DOCNO>NCT00088504</DOCNO>
	<brief_summary>This trial design test whether addition merimepodib ( MMPD ) standard therapy pegylated interferon ribavirin result positive treatment response people previously respond therapy . Approximately 315 subject enrol research study approximately 55 clinical site United States . There three study group . Everyone study receive Pegasys® ( pegylated interferon ) Copegus® ( ribavirin ) normally prescribed dos . Two group also receive study drug merimepodib ( MMPD ) twice day , one group dose level test . The third group take placebo instead MMPD , Pegasys® Copegus® . After first 24 week treatment , blood test do see subject respond treatment . If responding , continue receive study treatment study another 24 week . If responding , stop study treatment . Everyone respond monitor 24 week last dose medication , see long response last . Evaluations perform study look safety Pegasys®/Copegus® MMPD placebo combination , see combination work measure Hepatitis C Virus blood . At clinical site perform study , subject may also participate additional test look metabolism drug , look immune response Hepatitis C virus infection treatment .</brief_summary>
	<brief_title>Merimepodib ( MMPD ) Triple Combination Treatment Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>The following summary inclusion exclusion criterion Merimepodib Triple Combination ( METRO ) trial . There also additional criterion , review staff clinical study site , make sure eligible study . Some criterion dependent result blood test test do clinical site . If sure whether meet criterion , please call clinical study site near , help figure might eligible study : You must diagnose Hepatitis C. You must treat pegylated interferon ( brand name Pegasys® PegIntron® ) ribavirin ( brand name Rebetol® Copegus® ) , least 12 week . However , receive one course combination therapy . You must `` nonresponder '' treatment , mean virus level blood always detectable . If respond treatment virus become detectable ( call `` relapse '' ) , would eligible . You must use illegal drug , history significant alcohol use , within last year start study . Pegasys® Copegus® recommend people illness . You good health general , illness would prevent use Pegasys® Copegus® . If know whether illness condition would prevent use medication , study doctor nurse review medical history determine . If woman child , must willing use two effective method birth control study 6 month last dose medication . You monthly pregnancy test time make sure become pregnant ( This recommend anyone take ribavirin , even clinical study. ) . If male , female partner must pregnant , must willing use birth control time study , 6 month last dose medication ( This recommend anyone take ribavirin , even clinical study . ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Hepatitis</keyword>
</DOC>